ࡱ> 685 6bjbjVV 4 <<6 ////C/ >WWWWW222  0#%B 22222 WW 2WW 2 :,Wīm/  0 .&&&h2222222 222 2222&222222222 : DRUG DEVELOPMENT AND BIO-BUSINESS (MRes (Consecutive)/MRes (Standard)/PgDip/PgCert) 91B2CSH9 (Consecutive)/91B2STH9 (Standard)/92CB2DBVX/93B2DBVZ Qualifications: A degree or equivalent qualification, at the prescribed standard in Medicine, Pharmacology, Pharmacy or a relevant Science subject (e.g. Biochemistry, Biomedical Sciences, Biology). Duration: 16 24 months full time or 32 28 months part time (MRes); 9 months (PgDip); 4 months (PgCert) Aim: To equip students for a career in drug development in academia or in the Biotechnology or Pharmaceutical industry. The MRes will focus on a research career. To achieve this, the programme will provide a multi-disciplinary approach to the study of drug discovery and development; mechanisms of drug development; mechanisms of drug action; preclinical and clinical trials; regulatory affairs. Bio-Business, understanding the business of science, will be a key element in this degree. The research project will provide hands on experience of research methods and techniques. This course is designed for students requiring 120 ECTS credits (240 SCQF credits) at Masters level in preparation for admission to a PhD programme requiring 300 ECTS credits. Content: This course is designed for students requiring 120 ECTS credits (240 SCQF credits) at Masters level in preparation for admission to a PhD programme requiring 300 ECTS credits. The taught courses will comprise lectures, tutorials, practical classes and small group teaching and directed self-learning. The curriculum includes aspects of drug discovery, drug development and drug design, as well as drug transport, metabolism and excretion, molecular biology and bioanalytical methods, e.g. mass spectroscopy, bio-business will introduce students to the commercial, legal (intellectual property) and ethical aspects of todays bio-business world. Flexibility allows students to study 120 taught credits in Academic Year 1 (September to April) with the option to return in Academic Year 2 (September) or to continue in Academic Year 1 from April to undertake the research project subject to approval of the Programme Coordinator. Students will be advised on the appropriate route prior to admission. Candidates shall be required to attend the following designated programmes of course:- Stage 1 (September to January) Compulsory courses: BT 5010 Small Molecular Drug Discovery (25 credit points) BT 5011 Introduction to Bio-business and Commercialisation of Bioscience (10 credit points) MT 5003 Drug Metabolism (15 credit points) MT 5008 Molecular Pharmacology (20 credit points) MT 5010 Basic Skills Induction (0 credit points) GS 50M1 Generic Skills (0 credit points) SK 5003 Information Skills (0 credit points) Stage 2 (February to April) Compulsory courses: BT 5502 Special Study Module 2 Biologic Therapies (25 credit points) BT 5508 Advanced Bio-Business (15 credit points) MT 5501 Pharmacovigilance (5 credit points) MT 5503 Pharmacokinetics (10 credit points) Electives (extra credits): MB 5015 Molecular Biology Basics & Cloning Practical (15 credit points) MT 55EP Careers & Employability for Postgraduates (0 credit points) PU 5005 Statistics (10 credit points) Stage 3 (May or September to April) MB 50RP Research Project (120 credit points) Assessment: By practical work, by written essays and by oral presentations or by a combination of these as prescribed for each course. The thesis will be assessed and there may be an oral examination on completion of the programme. Candidates must pass all courses at an appropriate standard for the award of the MRes degree. X Y [ d WX23FG+npܻܢܔܔ~r~fhk[hH_>*OJQJhH_hH_6OJQJhH_hH_OJQJhH_>*OJQJ^Jh$fhH_6OJQJ^Jh$fhH_>*OJQJ^JhhH_OJQJhH_6OJQJhH_6OJQJ^JhC!hH_OJQJ^JhH_OJQJ^JhC!hH_6OJQJ^JhH_hH_OJQJ(TZ [   XY23G: SgdH_gdH_  D%dgdH_:m=n+p3456gd-gd[!gdH_ SgdH_ SgdH_23456Ĺ h-hCJh[!OJQJ^JhH_5CJOJQJh hH_OJQJhH_OJQJhH_6OJQJhH_6>*OJQJhH_hH_OJQJhH_>*OJQJ 21h:p[=. A!"#$% j 666666666vvvvvvvvv66666>66666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH N`N  Normal$a$ CJOJPJQJ_HmH sH tH `` + Heading 2$<@&$56CJOJPJQJ\]^JaJ>@>   Heading 3$d8@&5XX = Heading 6 <@&5CJOJPJQJ\^JaJRR "2^ Heading 7 <@&CJOJPJQJ^JaJXX N$ Heading 8 <@&6CJOJPJQJ]^JaJDA D Default Paragraph FontRiR 0 Table Normal4 l4a (k ( 0No List PP  Heading 3 Char5CJOJPJQJ^JaJ\\ +Heading 2 Char(56CJOJPJQJ\]^JaJtH 44 +Header  9r B!B + Header CharCJOJPJQJtH V1V =Heading 6 Char"5CJOJPJQJ\^JaJtH PAP "2^Heading 7 CharCJOJPJQJ^JaJtH JZRJ w0 Plain Text$a$CJOJQJ^JtH FaF w0Plain Text CharOJPJQJ^JVQrV ft Body Text 3$ 0d6a$ 5OJQJPP ftBody Text 3 Char5CJOJPJQJtH VV N$Heading 8 Char"6CJOJPJQJ]^JaJtH 6U6 mO Hyperlink >*B*phPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] 6 6 :6 8@0(  B S  ?#'6:FKLRDHv &*8XY8458458zp>}z<<^<`o(.^`o(()zLz^z`L.J J ^J `.  ^ `.L^`L.^`.^`.ZLZ^Z`L. ^`OJQJo(^`OJQJ^Jo(o pp^p`OJQJo( @ @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o PP^P`OJQJo(}zzp         TQ BkwgH J&d =gu(,v[!)"Z%l.3g8[=Q@B|BCJqKLyLw}MmOk,QEuW^]"2^H_a;ataEc%'gQ=gy&jDzj\Al(tftvYxH y%z7g|4&}?7}sl=w ~(u.t9aj+M7R.~N$h-mO|5$mg;Sdz9B}%R9g68@6@Unknown G*Ax Times New Roman5Symbol3. *Cx Arial7.{ @CalibriY CG TimesTimes New Roman7K@Cambria?= *Cx Courier New;WingdingsA BCambria Math"qhx=fx=f  !r0//3HP $P 2!xxRobertRobert  Oh+'0 px  RobertNormalRobert2Microsoft Office Word@@m@m ՜.+,0 hp|  /  Title  !"#$&'()*+,./012347Root Entry Fm91Table(&WordDocument4 SummaryInformation(%DocumentSummaryInformation8-CompObjy  F'Microsoft Office Word 97-2003 Document MSWordDocWord.Document.89q